Entellus Medical (ENTL) Upgraded at ValuEngine

Entellus Medical (NASDAQ:ENTL) was upgraded by investment analysts at ValuEngine from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Thursday.

Several other analysts also recently weighed in on ENTL. Piper Jaffray Companies restated a “buy” rating and set a $21.00 price objective on shares of Entellus Medical in a research report on Tuesday, August 22nd. BidaskClub upgraded shares of Entellus Medical from a “hold” rating to a “buy” rating in a research report on Saturday, August 19th. Canaccord Genuity restated a “hold” rating and set a $17.00 price objective on shares of Entellus Medical in a research report on Tuesday, October 17th. Finally, Zacks Investment Research upgraded shares of Entellus Medical from a “sell” rating to a “buy” rating and set a $23.00 price objective for the company in a research report on Monday, October 9th. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and three have issued a buy rating to the company’s stock. The company currently has an average rating of “Hold” and a consensus target price of $20.40.

Shares of Entellus Medical (ENTL) traded up $7.98 during trading hours on Thursday, hitting $23.99. 9,497,110 shares of the stock traded hands, compared to its average volume of 201,924. The company has a quick ratio of 1.71, a current ratio of 1.92 and a debt-to-equity ratio of 0.32. Entellus Medical has a twelve month low of $11.47 and a twelve month high of $24.13.

In other news, VP Stephen R. Paidosh sold 25,000 shares of Entellus Medical stock in a transaction on Wednesday, September 13th. The shares were sold at an average price of $17.54, for a total value of $438,500.00. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Brian E. Farley sold 101,319 shares of Entellus Medical stock in a transaction on Thursday, December 7th. The shares were sold at an average price of $23.85, for a total transaction of $2,416,458.15. The disclosure for this sale can be found here. Insiders sold a total of 193,469 shares of company stock worth $4,157,111 over the last ninety days. Corporate insiders own 7.70% of the company’s stock.

Several institutional investors have recently made changes to their positions in ENTL. Aisling Capital LLC acquired a new position in shares of Entellus Medical in the 3rd quarter valued at $9,759,000. Frontier Capital Management Co. LLC increased its stake in Entellus Medical by 85.0% in the 2nd quarter. Frontier Capital Management Co. LLC now owns 866,370 shares of the medical technology company’s stock valued at $14,347,000 after buying an additional 397,953 shares during the period. Tekla Capital Management LLC acquired a new position in Entellus Medical in the 2nd quarter valued at $5,655,000. Nicholas Company Inc. increased its stake in Entellus Medical by 1,052.3% in the 2nd quarter. Nicholas Company Inc. now owns 247,685 shares of the medical technology company’s stock valued at $4,101,000 after buying an additional 226,190 shares during the period. Finally, Vanguard Group Inc. increased its stake in Entellus Medical by 77.8% in the 1st quarter. Vanguard Group Inc. now owns 424,823 shares of the medical technology company’s stock valued at $5,862,000 after buying an additional 185,833 shares during the period. 78.76% of the stock is currently owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY WARNING: This story was posted by The Lincolnian Online and is the sole property of of The Lincolnian Online. If you are accessing this story on another publication, it was illegally stolen and reposted in violation of US and international trademark and copyright law. The legal version of this story can be read at https://www.thelincolnianonline.com/2017/12/08/entellus-medical-entl-upgraded-at-valuengine.html.

About Entellus Medical

Entellus Medical, Inc is a medical technology company. The Company is focused on delivering patient and physician experiences through products designed for the minimally invasive treatment of chronic and recurrent sinusitis in both adult and pediatric patients. Its three core product lines, XprESS Multi-Sinus Dilation Systems, MiniFESS Surgical Instruments, and FocESS Imaging & Navigation, are designed to enable ear, nose and throat (ENT), physicians to perform a range of procedures in the ENT physician office and to simplify operating room-based treatment.

Analyst Recommendations for Entellus Medical (NASDAQ:ENTL)

Receive News & Ratings for Entellus Medical Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Entellus Medical Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply